Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Kinetics of Metabolic Cofactors in NAFLD (NAFLDCOFCAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03838822
Recruitment Status : Completed
First Posted : February 12, 2019
Last Update Posted : February 15, 2019
Sponsor:
Collaborators:
Karolinska Institutet
Chalmers University of Technology
Information provided by (Responsible Party):
Hanns-Ulrich Marschall, Sahlgrenska University Hospital, Sweden

Tracking Information
First Submitted Date  ICMJE February 4, 2019
First Posted Date  ICMJE February 12, 2019
Last Update Posted Date February 15, 2019
Actual Study Start Date  ICMJE September 1, 2018
Actual Primary Completion Date November 1, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 12, 2019)
  • Changes of plasma levels of nicotinamide riboside measured by mass spectrometry [ Time Frame: Twenty-four hours after administration ]
    Plasma levels of nicotinamide riboside by UPLCMSMS at 8 time points during 24h after administration
  • Changes of plasma levels of L-carnitine measured by mass spectrometry [ Time Frame: Twenty-four hours after administration ]
    Plasma levels of L-carnitine (nM) measured by UPLCMSMS at 8 time points during 24h after administration
  • Changes of plasma levels of L-serine measured by mass spectrometry [ Time Frame: Twenty-four hours after administration ]
    Plasma levels of L-serine (nM) measured by UPLCMSMS at 8 times points during 24h after administration
  • Changes of plasma levels of N-acetylcystein measured by mass spectrometry [ Time Frame: Twenty-four hours after administration ]
    Plasma levels of N-acetylcystein (nM) measured by UPLCMSMS at 8 times points during 24h after administration
Original Primary Outcome Measures  ICMJE
 (submitted: February 11, 2019)
  • Changes of plasma levels of nicotinamide riboside measured by mass spectrometry [ Time Frame: Twenty-four hours after administration ]
    Plasma levels of nicotinamid riboside by UPLCMSMS at 8 time points during 24h after administration
  • Changes of plasma levels of L-carnitine measured by mass spectrometry [ Time Frame: Twenty-four hours after administration ]
    Plasma levels of L-carnitin (nM) measured by UPLCMSMS at 8 time points during 24h after administration
  • Changes of plasma levels of L-serine measured by mass spectrometry [ Time Frame: Twenty-four hours after administration ]
    Plasma levels of L-serine (nM) measured by UPLCMSMS at 8 times points during 24h after administration
  • Changes of plasma levels of N-acetylcystein measured by mass spectrometry [ Time Frame: Twenty-four hours after administration ]
    Plasma levels of N-cetylcystein (nM) measured by UPLCMSMS at 8 times points during 24h after administration
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 11, 2019)
  • Changes in the plasma level of metabolites associated with the supplementation of metabolic co-factors. [ Time Frame: Twenty-four hours after administration of combined cofactors ]
    Untargeted metabolomic analysis using mass spectrometry. (Untargeted = not pre-specified in terms of outcome)
  • Changes in the plasma level of inflammation-related proteins associated with the supplementation of metabolic co-factors. [ Time Frame: Twenty-four hours after administration of combined cofactors ]
    Changes in the plasma level of inflammation related proteins associated with the supplementation of metabolic co-factors.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Kinetics of Metabolic Cofactors in NAFLD
Official Title  ICMJE Kinetics of Metabolic Cofactors After Oral Supplementation in Healthy Subjects
Brief Summary

There is a strong correlation between major adverse health consequences of obesity and development of non-alcoholic fatty liver disease (NAFLD). NAFLD is characterized by abnormal hepatic accumulation of triglycerides and other lipids. It has become a worldwide health problem that accelerates cirrhosis, type 2 diabetes mellitus (T2DM), and especially premature cardiovascular morbidity and mortality.

The plasma level of glutathione (GSH) is typically depleted in individuals with metabolism related disorders. However, cellular GSH levels cannot be increased by supplementing GSH and it must be synthesized within the liver either de novo or by salvation pathway. The level of GSH is not enough to maintain and regulate the thiol redox status of the liver in subjects with high hepatic steatosis at fasting stage due to the depletion of glycine. Glycine can be synthesized via the interconversion of serine. It has been shown that the serine synthesis is downregulated in patients with NAFLD and supplementation of serine has attenuated alcoholic fatty liver by enhancing homocysteine metabolism in mice and rats. Depleted liver glutathione is also restored by the administration of N-acetylcystein as in acetaminophen poising. L-carnitine and nicotinamide that both stimulate the transfer of fatty acids from cytosol to mitochondria have been identified as two additional cofactors that are depleted in patients with NAFLD.

In this study, the kinetics in blood of pivotal metabolic cofactors, serine, L-carnitine, N-acetylcystein and nicotinamide after single and simultaneous dietary supplementation, are measured.

Detailed Description

In 10 healthy subjects with BMI <30 kg/m2 the plasma concentrations of 4 natural compounds (nicotinamide riboside, L-carnitine, L-serine and N-acetylcystein) are measured by ultra-performance liquid chromatography-tandem mass spectrometry (UPLCMSMS) after individual and combined administration, on five consecutive days and at every hour during 9 hours after administration. The study will start at 8:00 every morning and at each time point, blood samples will be collected.

The taste and any potential sensing of the co-factors such as vertigo, nausea, bowel movement will be recorded.

Each participant will receive one oral dose of Day 1: 1 g nicotinamide riboside; Day 2: 3 g L-carnitine; Day 3: 5 g N-acetylcystein; Day 4: 20 g L-serine; Day 5: combined 1 g nicotinamide riboside, 3 g L-carnitine, 5 g N-acetylcystein, and 20 g L-serine

In addition, untargeted metabolomics analysis as well as O-link proteomics analysis we be performed to study effect of the administered cofactors.

Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE Dietary Supplement: Cofactors
Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
Study Arms  ICMJE Experimental: Intervention
Oral administration of cofactors, 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
Intervention: Dietary Supplement: Cofactors
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 11, 2019)
10
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 1, 2018
Actual Primary Completion Date November 1, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Healthy without any medication, no smokers, no obesity

Exclusion Criteria:

Any known disease, obesity

Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years to 40 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Sweden
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03838822
Other Study ID Numbers  ICMJE Cofactor Calibration 1.0
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Hanns-Ulrich Marschall, Sahlgrenska University Hospital, Sweden
Study Sponsor  ICMJE Sahlgrenska University Hospital, Sweden
Collaborators  ICMJE
  • Karolinska Institutet
  • Chalmers University of Technology
Investigators  ICMJE
Principal Investigator: Hanns-Ulrich Marschall, Prof Sahlgrenska University Hospital, Sweden
PRS Account Sahlgrenska University Hospital, Sweden
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP